Background: Anti-cyclic citrullinated peptide (CCP) antibodies proved to have a better diagnostic performance respect to rheumatoid factors (RF) in the diagnosis of rheumatoid arthritis (RA). One third of RA patients has an Elderly Onset of the disease (>60 years)(EORA) and it is still debated if this subset has different clinical and laboratory features respect to that with a Younger Onset (YORA). Objectives: Aim of this study was to evaluate if anti-CCP antibody determination could help in discriminating EORA from YORA. Methods: We studied retrospectively 44 EORA patients (M/F = 11/33; mean age = 71.65 yrs; mean disease duration = 49.05 months; mean age at onset = 70.75 yrs) and 44 YORA patients (M/F = 7/37; mean age = 48.3 yrs; mean disease duration = 66.5 months; mean age at onset = 41.6 yrs). On previously collected serum samples from all the patients, anti-CCP antibodies were researched by ELISA method (INOVA Diagnostics). Main clinical (number of painful/swollen joints, morning stiffness) and laboratory data (ESR, CRP, RF) were reviewed. Results: 77.3% of EORA patients (34/44) and 84.1% of YORA patients (37/44) had anti-CCP antibodies. RF were found in 31 (70%) and 31 (70%) of EORA and YORA patients respectively. In those RF negative patients (13 EORA and 13 YORA) we found anti-CCP antibodies in 15.4% of EORA (2 cases) respect to 38.5% of YORA (5 cases). We did not find any statistically significant difference among the other examined clinical and laboratory features. Conclusion: Our preliminary results showed that anti-CCP test is positive in similar percentages both in EORA and YORA patients suggesting that this autoantibody does not permit to discriminate these two subsets. However the evidence of a higher sensitivity for anti-CCP respect to RF detection strengthens its usefulness as an adjunctive diagnostic tool in both EORA and YORA cases. References: Yazici Y et al. Rheum Dis Clin North Am 2000; 26: 517-26. Schellekens GA et al. Arthritis Rheum 2000; 43: 155-63. Lopez-Hoyos M et al. Rheumatology 2004; 43: 655-7.

Anti-cyclic citrullinated peptide antibodies in elderly onset rheumatoid arthritis / Riccieri, Valeria; V., Macri; V., Germano; Vasile, Massimiliano; Sciarra, Iliana; Scrivo, Rossana; Spadaro, Antonio; Valesini, Guido. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - STAMPA. - 65:(Suppl. 2)(2006), pp. 300-300. ((Intervento presentato al convegno Annual European Congress of Rheumatology (EULAR 2006) tenutosi a Amsterdam, NETHERLANDS nel JUN 21-24, 2006.

Anti-cyclic citrullinated peptide antibodies in elderly onset rheumatoid arthritis

RICCIERI, Valeria;VASILE, MASSIMILIANO;SCIARRA, ILIANA;SCRIVO, Rossana;SPADARO, Antonio;VALESINI, Guido
2006

Abstract

Background: Anti-cyclic citrullinated peptide (CCP) antibodies proved to have a better diagnostic performance respect to rheumatoid factors (RF) in the diagnosis of rheumatoid arthritis (RA). One third of RA patients has an Elderly Onset of the disease (>60 years)(EORA) and it is still debated if this subset has different clinical and laboratory features respect to that with a Younger Onset (YORA). Objectives: Aim of this study was to evaluate if anti-CCP antibody determination could help in discriminating EORA from YORA. Methods: We studied retrospectively 44 EORA patients (M/F = 11/33; mean age = 71.65 yrs; mean disease duration = 49.05 months; mean age at onset = 70.75 yrs) and 44 YORA patients (M/F = 7/37; mean age = 48.3 yrs; mean disease duration = 66.5 months; mean age at onset = 41.6 yrs). On previously collected serum samples from all the patients, anti-CCP antibodies were researched by ELISA method (INOVA Diagnostics). Main clinical (number of painful/swollen joints, morning stiffness) and laboratory data (ESR, CRP, RF) were reviewed. Results: 77.3% of EORA patients (34/44) and 84.1% of YORA patients (37/44) had anti-CCP antibodies. RF were found in 31 (70%) and 31 (70%) of EORA and YORA patients respectively. In those RF negative patients (13 EORA and 13 YORA) we found anti-CCP antibodies in 15.4% of EORA (2 cases) respect to 38.5% of YORA (5 cases). We did not find any statistically significant difference among the other examined clinical and laboratory features. Conclusion: Our preliminary results showed that anti-CCP test is positive in similar percentages both in EORA and YORA patients suggesting that this autoantibody does not permit to discriminate these two subsets. However the evidence of a higher sensitivity for anti-CCP respect to RF detection strengthens its usefulness as an adjunctive diagnostic tool in both EORA and YORA cases. References: Yazici Y et al. Rheum Dis Clin North Am 2000; 26: 517-26. Schellekens GA et al. Arthritis Rheum 2000; 43: 155-63. Lopez-Hoyos M et al. Rheumatology 2004; 43: 655-7.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/481169
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact